Cardinal Health周四盘前下跌 19亿美元收购交易致股价下挫

Core Viewpoint - Cardinal Health announced the acquisition of UroGen Pharma for $1.9 billion, leading to a decline in its stock price [1] Group 1: Acquisition Details - The acquisition is a cash transaction valued at $1.9 billion [1] - UroGen Pharma is valued at $16 per share, representing a 14% premium over its closing price on Tuesday [1] Group 2: Market Reaction - Following the announcement, Cardinal Health's stock price initially dropped by 4.2% during trading [1] - The stock ultimately closed down 2.7% at $102.45 [1]